SAMHD1 controls innate immunity by regulating condensation of immunogenic self RNA.
Aicardi-Goutières syndrome
RNA
SAMHD1
autoinflammation
condensate
dsRNA
innate immunity
phase separation
stress granules
type I interferon
Journal
Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571
Informations de publication
Date de publication:
06 10 2022
06 10 2022
Historique:
received:
14
12
2021
revised:
07
07
2022
accepted:
26
08
2022
pubmed:
24
9
2022
medline:
12
10
2022
entrez:
23
9
2022
Statut:
ppublish
Résumé
Recognition of pathogen-derived foreign nucleic acids is central to innate immune defense. This requires discrimination between structurally highly similar self and nonself nucleic acids to avoid aberrant inflammatory responses as in the autoinflammatory disorder Aicardi-Goutières syndrome (AGS). How vast amounts of self RNA are shielded from immune recognition to prevent autoinflammation is not fully understood. Here, we show that human SAM-domain- and HD-domain-containing protein 1 (SAMHD1), one of the AGS-causing genes, functions as a single-stranded RNA (ssRNA) 3'exonuclease, the lack of which causes cellular RNA accumulation. Increased ssRNA in cells leads to dissolution of RNA-protein condensates, which sequester immunogenic double-stranded RNA (dsRNA). Release of sequestered dsRNA from condensates triggers activation of antiviral type I interferon via retinoic-acid-inducible gene I-like receptors. Our results establish SAMHD1 as a key regulator of cellular RNA homeostasis and demonstrate that buffering of immunogenic self RNA by condensates regulates innate immune responses.
Identifiants
pubmed: 36150385
pii: S1097-2765(22)00851-6
doi: 10.1016/j.molcel.2022.08.031
pii:
doi:
Substances chimiques
Antiviral Agents
0
Interferon Type I
0
RNA, Double-Stranded
0
Exonucleases
EC 3.1.-
SAM Domain and HD Domain-Containing Protein 1
EC 3.1.5.-
SAMHD1 protein, human
EC 3.1.5.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3712-3728.e10Subventions
Organisme : British Heart Foundation
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests A.A.H. is a founder of Dewpoint Therapeutics and Caraway Therapeutics and is an advisor to Dewpoint therapeutics. S.A. is an advisor to Dewpoint Therapeutics.